Part I Overview Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression. We are a clinical-stage biotechnology company committed to overcoming t...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001404644-26-000019 | EDGAR | 103K words |
| 2025-03-24 | 2024-12-31 | 0001404644-25-000012 | EDGAR | — |
| 2024-03-18 | 2023-12-31 | 0001404644-24-000020 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0001628280-23-008602 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001628280-22-004491 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001628280-21-005630 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001193125-20-071545 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001193125-19-066506 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001193125-18-079210 | EDGAR | — |
| 2017-03-09 | 2016-12-31 | 0001193125-17-076939 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001404644-25-000101 | EDGAR | 64K words |
| 2025-08-11 | 2025-06-30 | 0001404644-25-000081 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001404644-25-000041 | EDGAR | — |
| 2024-11-18 | 2024-09-30 | 0001404644-24-000104 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001404644-24-000086 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001404644-24-000057 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001628280-23-038797 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001628280-23-028856 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016425 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001628280-22-029833 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001628280-22-021923 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001628280-22-013306 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001404644-26-000012 | EDGAR | 4K words |
| 2026-02-26 | 0001404644-26-000006 | EDGAR | — |
| 2026-01-12 | 0001404644-26-000003 | EDGAR | — |
| 2025-11-13 | 0001404644-25-000103 | EDGAR | — |
| 2025-11-12 | 0001404644-25-000098 | EDGAR | — |
| 2025-11-06 | 0001404644-25-000091 | EDGAR | — |
| 2025-10-09 | 0001404644-25-000088 | EDGAR | — |
| 2025-08-11 | 0001404644-25-000082 | EDGAR | — |
| 2025-06-30 | 0001404644-25-000070 | EDGAR | — |
| 2025-06-12 | 0001404644-25-000053 | EDGAR | — |
227 total filings indexed. 195 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001404644 |
| Ticker | NGNE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.neurogene.com |
| Listed | 2023-12-19 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report